D. Hübschmann

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

C. von Kalle, S. Fröhling, E. Schröck, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

A. Schneeweiss, M. Golatta, J. Heil, 2022, ESMO open.

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway

S. Fröhling, V. Glutsch, A. Rosenwald, 2021, The British journal of dermatology.